The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.
|State||Published - Feb 2021|
Bibliographical notePublisher Copyright:
© 2021 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health